Film Session Q&A : Single-port access Laparoscopic complete excision for deep infiltrating endometriosis (초)

김상운 ( Sang Wun Kim ),( Ji Heum Paek ),( Ga Won Yim ),( San Hui Lee ),( Maria Lee ),( Eun Ji Nam ),( Young Tae Kim ) 대한산부인과학회 2010 대한산부인과학회 학술대회 Vol.96 No.-

난소암 조직에서 HLA-G유전자 발현과 예후 인자와의 상관성

홍원기 ( Won Ki Hong ),김영태 ( Young Tae Kim ),윤보성 ( Bo Sung Yoon ),김상운 ( Sang Wun Kim ),김성훈 ( Sung Hoon Kim ),김재훈 ( Jae Hoon Kim ),김재욱 ( Jae Wook Kim ),박용원 ( Yong Won Park ) 대한산부인과학회 2005 Obstetrics & Gynecology Science Vol.48 No.12

로봇 복강경하 전자궁절제술 한국최초 임상보고

김영태 ( Young Tae Kim ),김상운 ( Sang Wun Kim ),윤보성 ( Bo Sung Yoon ),남은지 ( Eun Ji Nahm ),허혜원 ( Hye Won Hur ),김성훈 ( Sung Hoon Kim ),김재훈 ( Jae Hoon Kim ),김재욱 ( Jae Wook Kim ) 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.12

Hysterectomy is one of the most common non-pregnancy-associated surgical techniques in the field of gynecology. Over the years, this laparoscopic approach has evolved to include both subtotal and total laparoscopic hysterectomy. Robot-assisted technology may attenuate the learning curve for complex laparoscopic procedures, leveling the playing field between conventional laparotomy practitioners and laparoscopists. The advantages of robotics, such as motion scaling, three-dimensional visualization, and articulated instrumentation, enables complex surgical procedures to be performed with greater dexterity, more quickly, and more easily by many surgeons. We have experienced a case of patient with carcinoma in situ of the uterine cervix treated by robotic surgery. We report the first case treated by robotic total laparoscopic hysterectomy with a brief review of literature.

방향 투영에 의한 인쇄체 한글의 기본 선소 추출에 관한 연구

김상운(Sang Woon Kim),이병래(Byeong Rae Lee),이규원(Gye Won Lee),박규태(Kyu Tae Park) 대한전기학회 1987 대한전기학회 학술대회 논문집 Vol.1987 No.7

GPT-2를 이용한 지식 그래프 완성

김상운(Sang-Woon Kim),신원철(Won-Chul Shin) Korean Institute of Information Scientists and Eng 2021 정보과학회논문지 Vol.48 No.12

Knowledge graphs become an important resource in many artificial intelligence (AI) tasks. Many studies are being conducted to complete the incomplete knowledge graph. Among them, interest in research that knowledge completion by link prediction and relation prediction is increasing. The most talked-about language models in AI natural language processing include BERT and GPT-2, among which KG-BERT wants to solve knowledge completion problems with BERT. In this paper, we wanted to solve the problem of knowledge completion by utilizing GPT-2, which is the biggest recent issue in the language model of AI. Triple information-based knowledge completion and path-triple-based knowledge completion were proposed and explained as methods to solve the knowledge completion problem using the GPT-2 language model. The model proposed in this paper was defined as KG-GPT2, and experiments were conducted by comparing the link prediction and relationship prediction results of TransE, TransR, KG-BERT, and KG-GPT2 to evaluate knowledge completion performance. For link prediction, WN18RR, FB15k-237, and UMLS datasets were used, and for relation prediction, FB15K was used. As a result of the experiment, in the case of link prediction in the path- triple-based knowledge completion of KG-GPT2, the best performance was recorded for all experimental datasets except UMLS. In the path-triple-based knowledge completion of KG-GPT2, the models relationship prediction work also recorded the best performance for the FB15K dataset.

간전이 위암환자의 치료 결과 및 예후

김은미,김세원,김상운,이경희,현명수,박원규,장재천,송선교,Kim, Eun-Mi,Kim, Se-Won,Kim, Sang-Woon,Lee, Kyung-Hee,Hyun, Myung-Soo,Park, Won-Kyu,Chang, Jae-Chun,Song, Sun-Kyo 대한위암학회 2006 대한위암학회지 Vol.6 No.4

목적: 간전이 위암환자들을 대상으로 치료 결과를 알아보고 생존 분석을 통해 예후를 확인하고자 하였다. 대상 및 방법: 1990년 3월부터 2006년 3월까지 영남대학교 영남의료원 내과 및 외과에 내원한 위암환자 중 간전이가 발견된 85예(동시성 62예, 이시성 23예)를 대상으로 후향적 연구를 시행하였다. 임상병리학적 인자와 위절제술, 간전이병소 절제술 및 항암화학요법 등 치료 관련 인자들에 대해 생존분석을 실시하였다. 결과: 간전이 위암환자들의 중앙생존기간은 11개월(동시성 11개월, 이시성 17개월)이었다. 동시성 간전이군의 경우 위절제율은 24.1%, 간전이병소 절제율은 16.1%였다. 간외 전이 동반율은 23.5%였고 생존기간에 차이가 있었다(P<0.05). 간전이 병소 절제 및 위절제군, 위절제군, 비절제군의 중앙생존기간은 각각 60개월 이상, 10개월 및 9개월이었다(Fig. 1, P<0.05). 이시성 간전이군의 경우 위암절제 후 무병생존기간의 중앙치는 8개월이었으며 초기병기와 간전이 빈도 사이에는 차이가 없었다. 동시성 간전이군에서는 단변량 분석 결과 간외 전이, 위절제술, 간전이 병소 절제술, 외과적 절제 형태 및 항암화학요법에 대한 반응이 유의하였고 다변량 분석 결과 간전이병소 절제술, 항암화학요법에 대한 반응 및 간외 전이가 독립적 예후인자였고, 이시성 간전이군에서는 간외 전이, 항암화학요법에 대한 반응 및 원발암 세포의 분화도가 유의하였고 간외 전이가 독립적 예후인자였다. 결론: 간전이 위암환자에서 예후는 간전이 병소의 절제, 원발 병소의 절제, 간외 전이 유무 및 항암화학요법에 대한 반응여부에 의해 결정되므로 치료에 있어 간외 전이가 없는 경우 보다 적극적인 절제 노력과 항암화학요법이 생존율 향상에 기여할 것으로 판단된다. Purpose: This study was conducted to evaluate the treatment outcomes and the prognosis for gastric cancer patients with hepatic metastasis. Materials and Methods: This retrospective study was based on the medical records of 85 gastric cancer patients with hepatic metastasis (62 synchronous and, 23 metachronous) who received chemotherapy with or without resectional therapy from March 1990 to March 2006. The survival rate was analyzed according to clinicopathologic factors and therapeutic factors, such as whether or not a gastrectomy, a hepatic resection, and/or chemotherapy had been performed. Results: The median survival of gastric cancer patients with hepatic metastasis was 11 months (synchronous: 11 months and metachronous: 17 months). The rates of gastrectomies and hepatic resections in the synchronous group were 24.1% and 16.1%, respectively A 23.5% prevalence of extra-hepatic metastasis was observed. The median survivals of patients who underwent a gastrectomy with a hepatic resection, a gastrectomy alone, and non-surgical treatment were 60, 18, and 9 months, respectively (P<0.05). The disease-free median survival of the metachronous group was 8 ($3{\sim}39$) months. There was no difference in initial pathologic stage and frequency of hepatic metastasis after the gastrectomy in the metachronous group. In the synchronous group, extra-hepatic metastasis, a gastrectomy as the operative procedure, a hepatic resection as the operative procedure and the response to chemotherapy were statistically significant in the univariate analysis, and a hepatic resection as the operative procedure, the response to chemotherapy, and extra-hepatic metastasis were independant prognostic factors identified by the multivariate analysis. In the metachronous group, extra-hepatic metastasis, the response to chemotherapy and differentiation were statistically significant in the univariate analysis, and extra-hepatic metastasis was an independent prognostic factor identified by the multivariate analysis. Conclusion: An aggressive surgical therapy and effective chemotherapy are necessary in the treatment of gastric cancer patients with hepatic metastasis. (J Korean Gastric Cancer Assoc 2006;6:237-243)

절제불능 위암 및 재발 위암환자에서 TS-1 단독 혹은 TS-1/CDDP 병용요법의 효과 및 부작용

김세원 ( Se Won Kim ),김상운 ( Sang Woon Kim ),송선교 ( Sun Kyo Song ) 영남대학교 기초/임상의학연구소 2007 Yeungnam University Journal of Medicine Vol.24 No.2S

Purpose:Although several chemotherapy regimens used against advanced and recurred gastric cancer have been studied extensively in an attempt to further improve the prognosis of patients, no standard chemotherapeutic regimens have been established. The aim of this study was to determine the anti-tumor efficacy and safety of TS-1 or TS-1 plus cisplatin (CDDP). Materials and Methods:From December 2004 to June 2007, we treated 43 patients with unresectable or recurred gastric cancer either with 80 mg/m2 of TS-1 for 28 days, which was followed by a 2-week rest, or with 80 mg/m2 of TS-1 for 28 days and 60 mg/m2 of CDDP on day 3 every 6 weeks. 1) Results:Tumor response rates in the primary chemotherapy group and in the recurrent group were 46.7% and 21.4%, respectively. The median survival rates in the primary and the recurrent group were 14 months and 8 months, and it was not significantly different. But the one-year survival rates according to the kinds of regimens (TS-1 or TS-1/CDDP group) were significantly different (P=0.0014). The incidences of grade 3 or 4 adverse effects were 18%, respectively. Conclusion:The anti-tumor efficacy and safety of TS-1 and TS-1 plus CDDP in unresectable or recurred gastric cancer patients seemed to be high with modest adverse effects, thus suggesting the possible use of this regimen for unresectable or recurred gastric cancer patients.

3기 위암 환자의 술 후 생존율 및 예후 인자 분석

장석원,김치호,김상운,송선교,Jang Seok-Won,Kim Chi-Ho,Kim Sang-Woon,Song Sun-Kyo 대한위암학회 2004 대한위암학회지 Vol.4 No.3

Purpose: There have been some controversies over the therapeutic principles of advanced gastric cancer, and the results of treatment have been variable, especially for stage III disease. This study was conducted to define the prognostic factors of stage III gastric cancer. Materials and Methods: This retrospective study was based on the medical records of 179 patients with stage III disease who received a gastrectomy from January 1990 to December 1994. The 5-year survival rate was analyzed according to the age, sex, tumor location, tumor size, Borrmann's type, depth of invasion, lymph-node metastasis, ratio of metastatic lymph nodes, type of surgical resection, extent of lymphnode dissection, curability of resection, postoperative chemotherapy, and pathological stage. The statistical analysis was done by using the Kaplan-Meier method, the log-rank test, and the Cox proportional hazards model. Results: The overall 5-year survival rate was $61.6\%$ the 5-year survival rates according to subgroup were $69.7\%$ for stage IIIa ($100\%$ for $T_{2}N_{2}$, $70.0\%$ for $T_{3}N_{1}$, $68.6\%$ for $T_{4}N_{0}$), and $54.1\%$ for stage IIIb ($T_{3}N_{2}$) (P<0.05). Among various clinicopathologic factors of stage III gastric cancer, the age of the patient, the tumor location, the gross type of tumor, the type of gastric resection, the extent of lymph-node dissection, the curability of resection, and the subgroups of stage III were statistically significant in the univariate survival analysis. The multivariate analysis defined the curability of resection, the extent of lymph-node dissection, the type of operation, the stage of disease, and the age of the patient as independent prognostic factors. Conclusion: A curative surgical resection and an extended lymph-node dissection are thought to be most important for improving the survival rate in stage III gastric cancer patients.

T2 위암환자의 침윤깊이에 따른 병리소견 및 예후의 차이

김세원 ( Se Won Kim ),송선교 ( Sun Kyo Song ),김상운 ( Sang Woon Kim ) 영남대학교 기초/임상의학연구소 2007 Yeungnam University Journal of Medicine Vol.24 No.2S

Purpose:A difference of a pathologic characteristic in proportion to depth of invasion analyzed in T2 gastric cancer and a difference of depth of invasion examined an influence to lymph node metastasis and prognosis. Materials and Methods:The clinicopathologic outcomes of 432 patients who underwent curative resection for pT2 stage gastric cancers from 1995 to 1999 were reviewed retrospectively. We are compared on lymphatic metastasis, stage distribution, histologic classification, Bormann`s classification, Lauren classification, vessel invasion, lymphatic invasion, neural invasion and 5-year survival rate of pT2 groups(mp vs. ss). 1) Results:pT2b(ss) group compare to pT2a(mp) in Lauren classification, ratio of diffused type was higher(p<0.05) and in Bormann classification, infiltration type was higher (p<0.01). Vessel and lymphatic invasion, neural invasion showed significant difference between pT2a(mp) and pT2b(ss) (p<0.01). Difference noted between pT2a(mp) and pT2b(ss) group in a lymph node metastatic rate, degree of a metastasis and stage distribution (p<0.01). On stratifying patients according to depth of invasion, 5-year suvival rate for those with pT2a(mp) group was significantly greater than those with pT2b(ss) group(82.4% vs. 47.4%, respectively: P<0.01). In this study, appeared with the significant prognostic factor in 5-year suvival rate which multivariate analysis, depth of invasion(P<0.05) and lymph node metastasis (P<0.01) that enforced the total gastric cancer patient who had T2 gastric cancer with the object noted, but for patients with accurately staged pN0 group, suvival characteristics were similar for pT2a (mp) and pT2b(ss) gastric cancer (P=0.97). Conclusion:The subclassification of pT2 gastric cancer into pT2a(mp) and pT2b(ss) is necessary to demonstrate their different prognosis.

재발 위암환자에서 2차 구제요법제로서의 Docetaxel을 포함한 항암화학요법의 치료 성적 및 부작용

김세원 ( Se Won Kim ),김상운 ( Sang Woon Kim ),송선교 ( Sun Kyo Song ) 영남대학교 기초/임상의학연구소 2007 Yeungnam University Journal of Medicine Vol.24 No.2S

Purpose:To investigate the efficacy and safety of docetaxel based chemotherapy as a secondline treatment in patients with metastatic or recurrent gastric cancer. Materials and Methods:Between January 2001 and March 2007, 28 patients with recurrent or metastatic gastric cancer were enrolled. The administered doses of decetaxel was 75 mg/m2 on day 1 and 5, cisplatin 60 mg/m2 on day 3, 5-FU 600 mg/m2 over 24 hrs on day 1 to day 5, every 4 weeks. The response was assessed every 2 cycles. The toxicities were evaluated for every course of chemotherapy according to National Cancer Institute-common toxicity criteria (NCI-CTC). 1) Results:For response rates, 3 (10.7%) partial response, 13 (46.4%) stable disease, and 12 (42.9%) progressive disease, respectively. The overall disease control rate was 57.1%. The median time to progression was 3.0 months (2-8 months). Median overall survival was 8 months (5-11 months). NCI-CTC grade 3 leukocytopenia occurred in 1 cases, grade 3 anemia in 1case and grade 3 nausea/vomiting in 2 cases. Conclusion:Docetaxel based chemotherapy has a tolerable efficacy with acceptable toxicities in patients with recurrent gastric cancer as a second-line treatment.